It Seems ESSA Pharma Inc. (EPIX) Will Go Down. Just Reaches 52 Week Low

July 17, 2017 - By Ellis Scott

The stock of ESSA Pharma Inc. (NASDAQ:EPIX) hit a new 52-week low and has $0.29 target or 6.00 % below today’s $0.31 share price. The 7 months bearish chart indicates high risk for the $10.18M company. The 1-year low was reported on Jul, 17 by If the $0.29 price target is reached, the company will be worth $610,800 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

About 287,062 shares traded or 198.98% up from the average. ESSA Pharma Inc. (NASDAQ:EPIX) has 0.00% since July 17, 2016 and is . It has underperformed by 16.70% the S&P500.

ESSA Pharma Inc. (NASDAQ:EPIX) Ratings Coverage

Among 2 analysts covering ESSA Pharma (NASDAQ:EPIX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ESSA Pharma had 3 analyst reports since April 12, 2016 according to SRatingsIntel. Noble Financial maintained ESSA Pharma Inc. (NASDAQ:EPIX) on Wednesday, June 7 with “Buy” rating. The stock of ESSA Pharma Inc. (NASDAQ:EPIX) has “Buy” rating given on Friday, February 17 by Noble Financial.

More notable recent ESSA Pharma Inc. (NASDAQ:EPIX) news were published by: which released: “ESSA Pharma Announces Closing of US$15 Million Private Placement” on January 14, 2016, also with their article: “ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for …” published on March 31, 2015, published: “Essa Pharma Inc.” on February 14, 2011. More interesting news about ESSA Pharma Inc. (NASDAQ:EPIX) were released by: and their article: “IIROC Trade Halt – ESSA Pharma Inc.” published on July 12, 2017 as well as‘s news article titled: “ESSA Pharma continues slide; shares down 36%” with publication date: June 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.